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This is a phase II dose escalation trial of carfilzomib in combinationwith thalidomide and dexamethasone  for induction and consoli-dation in transplant-eligible patients with newly diagnosed multi-
ple myeloma (NDMM). The results of four dose levels are reported.
Induction therapy consisted of four cycles of carfilzomib 20/27 mg/m2
(n=50), 20/36 mg/m2 (n=20), 20/45 mg/m2 (n=21), and 20/56 mg/m2
(n=20) on days 1, 2, 8, 9, 15, 16 of a 28-day cycle; thalidomide 200 mg on
day 1 through 28 and dexamethasone 40 mg weekly. Induction therapy
was followed by high-dose melphalan and autologous stem cell trans-
plantation and consolidation therapy with four cycles of carfilzomib,
thalidomide and dexamethasone in the same schedule except a lower
dose of thalidomide (50 mg).  Very good partial response rate  or better
and complete response  rate or better after induction therapy were 65%
and 18%, respectively, increasing to 86% and 63%, respectively, after
consolidation therapy. In all cohorts combined, after a median follow up
of 58.7 months, median progression-free survival was 58 months
(95%CI: 45-67 months). Median overall survival was 83 months (95%CI:
83 months-not reached). Grade 3/4 adverse events consisted mainly of
infections, respiratory disorders, skin and vascular disorders in 11%, 8%,
9%, and 9%, respectively. Grade 3 polyneuropathy was only reported in
one patient. Cardiac events were limited: grade 3/4 in 5% of patients.
Carfilzomib, thalidomide and dexamethasone as induction and consoli-
dation treatment after  high-dose melphalan and autologous stem cell
transplantation is highly efficacious and safe in transplant-eligible
patients with NDMM. This study was registered as #NTR2422 at
http://www.trialregister.nl
Introduction
Survival rates in patients with multiple myeloma (MM) have significantly
improved during the last decades. However, eventually the majority of patients
progress and the need for new therapeutic approaches remains. In transplant-eli-
gible patients with newly diagnosed multiple myeloma (NDMM), depth of
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ABSTRACT
response before and after high-dose melphalan/autolo-
gous stem cell transplantation (HDM/ASCT) is associated
with improvement in progression-free survival (PFS) and
overall survival (OS).1-5 Therefore, it is important to select
the appropriate induction and consolidation therapy in
order to achieve a maximum response after ASCT and to
maintain or even increase this response during consolida-
tion therapy and thereafter. 
Standard induction treatment consists of triple therapy
including a proteasome inhibitor, and/or an immunomod-
ulatory drug and dexamethasone. The combination of
bortezomib, thalidomide and dexamethasone (VTD) has
been extensively investigated in transplant-eligible
patients with NDMM.6-8 However, treatment with borte-
zomib is associated with higher rates of polyneuropathy
(PN) and a consequent discontinuation of treatment.7,8 It
is important to use a regimen that is highly effective and
safe in patients with NDMM. This could improve treat-
ment adherence and subsequently outcome after induc-
tion and consolidation therapy.
Carfilzomib is a selective proteasome inhibitor with
irreversible binding to the constitutive proteasome and
immunoproteasome. It is approved in the United States
and in Europe as a single-agent for the treatment of
patients with relapsed and/or refractory MM (RRMM).
Carfilzomib is approved at a dose of 27 mg/m2 in combi-
nation with lenalidomide and dexamethasone in RRMM
based on the data from the ASPIRE trial showing a supe-
rior PFS of median 26.3 months versus 17.4 months when
patients were treated with
lenalidomide/dexamethasone.9 Carfilzomib is also
approved at a dose of 56 mg/m2 in combination with dex-
amethasone, based on data from the ENDEAVOR trial
showing a superior PFS over bortezomib/dexamethasone
of median 18.7 months versus 9.4 months (P<0.0001).10
Previous trials showed that the incidence of PN with
carfilzomib is lower compared to bortezomib.9-11
Carfilzomib has not yet been approved for treatment in
NDMM in Europe. Recent trials in patients with NDMM,
using different treatment regimens, showed high
response rates.12-15 A phase I/II trial of patients with
NDMM treated with carfilzomib at a maximum dose of
36 mg/m2 combined with lenalidomide and low-dose
dexamethasone showed a very good partial response
(VGPR) rate of 81%. PFS at 24 months was 92%.12
We previously initiated a Phase II dose-escalation trial
of carfilzomib combined with thalidomide and dexam-
ethasone. The combination of a proteasome inhibitor and
an immunomodulating agent has a proven synergystic
effect.6 Moreover, thalidomide is an effective and afford-
able drug available in many countries.
In NDMM, there is no consensus as to the optimum
dose level of carfilzomib, implicating the need for dose-
finding trials. The goal of this trial was to investigate the
efficacy of this combination at various dose levels of
carfilzomib  in NDMM. Results of the first three cohorts
of this Carthadex trial were published in 2015.11 Overall
response rate (ORR) after induction therapy was 90%
with a VGPR rate of 68%. PFS at 36 months was 72%.
The combination of carfilzomib, thalidomide and dexam-
ethasone (KTd) was well tolerated.11 Four different dose
levels were included in this trial based on the hypothesis
that a higher dose level  induces a higher response rate.12,16
We report herein the results of our dose escalation
cohorts with a long follow up. This is the first study using
KTd for both induction and consolidation therapy and
comparing different dose levels.
Methods
Patients
Transplant-eligible patients with NDMM, aged 18-65
years, were eligible for enrollment. Patients were required to
have a World Health Organization (WHO) performance status
of 0-3; WHO 3 was allowed only when caused by MM and not
by co-morbid conditions. 
Patients were ineligible if they had grade 3/4 polyneuropathy
(PN) or grade 2 painful PN, severe cardiac dysfunction (New
York Heart Association class II-IV), known intolerance of
thalidomide, systemic amyloid light-chain amyloidosis, non-
secretory MM, Waldenström macroglobulinemia or IgM MM,
creatinine clearance <15 mL/min, absolute neutrophil count
<1.0x109/L, platelets <75x109/L, hemoglobin <4.9 mmol/L,
active malignancy during the past five years with the exception
of basal carcinoma of the skin or stage 0 cervical carcinoma.
This independent investigator-initiated multi-institutional
study was conducted in accordance with the Declaration of
Helsinki, the International Conference on Harmonization
Guidelines for Good Clinical Practice, and the European Clinical
Trial Directive as implemented under Dutch law. The protocol
was approved by institutional review boards and ethics com-
mittees. All patients gave informed consent.
Study design and treatment
This single-arm, open-label, phase II trial was conducted at
eight hematology centers. Patients were treated with four cycles
KTd of a 28-day cycle for induction therapy. Carfilzomib was
administered in a 30-minute infusion. The dose in the first dos-
ing cohort was 20 mg/m2 on days 1 and 2 and was escalated to
a dose of 27 mg/m2 on days 8, 9, 15 and 16 of cycle 1 and on
days 1, 2, 8, 9, 15 and 16 of cycles 2-4. Thalidomide 200 mg was
given orally on days 1 through 28 and dexamethasone 40 mg
was given orally on days 1, 8, 15 and 22. Induction therapy was
followed by stem cell harvest after cyclophosphamide priming
(2-4 mg/m2 i.v.) and daily 10 mg/kg granulocyte colony-stimulat-
ing factor. Hereafter, patients received high-dose melphalan
(HDM, 200 mg/m2) and ASCT followed by consolidation treat-
ment with four cycles of KTd in the same schedule and dose as
induction treatment except that the dose of thalidomide was 50
mg instead of 200 mg. The dose of carfilzomib was escalated to
20/36 mg/m2, 20/45 mg/m2 and 20/56 mg/m2 in cohorts  2, 3 and
4, respectively. Under the study protocol, patients were required
to maintain adequate hydration. In addition, patients were treat-
ed prophylactically with antibiotics (ciprofloxacin or another
fluoroquinolone) and with antiviral medication (acyclovir or a
similar anti varicella agent). All patients received antithrombotic
prophylaxis with aspirin in case of low thrombotic risk or with
low-molecular-weight heparin in patients with pre-existing
thrombotic risk factors.17
The primary end point of the study was response after induc-
tion therapy and overall response, specifically complete
response (CR) and VGPR. Secondary end points were efficacy
and safety, maximum tolerated dose (MTD), dose limiting toxi-
cities (DLT), PFS and overall survival (OS). PFS was defined as
time from registration to progression or death, whichever came
first. OS was calculated from registration to death from any
cause; patients still alive at last contact were censored.
This study was registered as #NTR2422 at http://www.trialreg-
ister.nl.
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Assessments
Treatment responses and disease progression were assessed by
study investigators and were classified according to International
Myeloma Working Group (IMWG) Uniform Response Criteria,
with categories for CR, VGPR, and partial response (PR).18 Toxicity
was assessed according to the National Cancer Institute Common
Terminology Criteria of Adverse Events version 4.0.19 Bone mar-
row analysis was performed at diagnosis to quantify myeloma cell
involvement. Molecular, cytogenetic and fluorescence in situ
hybridization (FISH) studies were performed on these samples.
CD138+ purified MM cells were used to determine the presence of
the following cytogenetic abnormalities: t(4;14)(p16;q32),
t(14;16)(q32;q32), del(13q), del(17p), 1p/q abnormalities, numerical
abnormalities of chromosome 9 or 11, and complex cytogenetic
abnormalities.11
Statistical analysis
This study was designed to investigate whether induction treat-
ment with KTd warrants further investigation in future trials. The
intention-to-treat principle was used for all analyses, restricted to
eligible patients. A CR + VGPR rate lower than 25% after induc-
tion treatment, was considered too low to warrant further investi-
gation in future trials; however, if the CR + VGPR rate was higher
than 45%, therapeutic activity was considered sufficiently high to
support further investigation. To reject the null hypothesis in favor
of the alternative hypothesis with power 1 - β=0.80 (two-sided sig-
nificance level α=0.05), a minimum of 41 patients should be
included. A 95% confidence interval (CI) was constructed around
the CR + VGPR rate after induction treatment and the null hypoth-
esis was rejected if the lower boundary was larger than 25%.
Predefined subgroup analyses were performed to investigate the
effect of risk status, using cytogenetic/FISH criteria, International
Staging System (ISS) stage and revised (R)-ISS stage, on response
and survival. In this trial, patients were considered to be high-risk if
they had t(4;14) and/or del(17p) and/or add(1q) and/or ISS stage III.  
Continuous and categorical data were summarized with
descriptive statistics. Survival end points were estimated using the
Kaplan-Meier method, and 95%CI were constructed. The log-
rank was used to evaluate differences in PFS and OS between sub-
groups. Statistical analysis was performed using Stata v15.1 soft-
ware (StataCorp, College Station, TX, USA). 
Results
Patients and treatment
One hundred and eleven patients were enrolled between
September 16th, 2010 and December 30th, 2013. The analysis
was based on data available as of February 27th, 2018 with
a median follow up of 58.7 months (range: 25.1-88.0
months). Four different dose levels were investigated (27
mg/m2, n=50; 36 mg/m2, n=20; 45 mg/m2, n=21; 56 mg/m2,
n=20). Baseline demographics and disease characteristics
are shown in Table 1. Median age was 58 years (range: 29-
66 years) and the male/female distribution 61%/39%. Nine
percent of patients had an R-ISS stage 3 and in 9% of
patients R-ISS stage was unknown, mainly due to missing
cytogenetics. A total of 39% of patients were classified as
high-risk based on cytogenetics and ISS stage; 41% of
patients were classified as standard risk. In 20% of patients,
risk status was unknown, mainly due to missing cytogenet-
ics. Seven patients had a history of grade 1/2 PN and two
patients a grade 3 PN at diagnosis; in nine patients, baseline
assessment of PN was missing at enrollment. A total of 5%
of patients had renal insufficiency with a creatinine ≥ 177
mmol/L at diagnosis.
All 111 patients started induction therapy with KTd
(Figure 1). Six patients discontinued treatment because of
the following adverse events (AE): grade 3 rash (carfilzomib
27 mg/m2), grade 2 fever with sepsis (carfilzomib 27
mg/m2), grade 1 hyponatremia (carfilzomib 27 mg/m2),
grade 2 exanthema (carfilzomib 27 mg/m2), grade 3 conges-
tive heart failure (carfilzomib 27 mg/m2), grade 3 pneu-
monitis (carfilzomib 36 mg/m2), grade 3 drug reaction with
eosinophilia and systemic symptoms (Dress syndrome)
(carfilzomib 56 mg/m2). One patient appeared not eligible
for further treatment and two patients discontinued treat-
ment due to progressive disease. Out of 111 patients, 102
(92%) continued treatment with high-dose cyclophos-
phamide and stem cell collection. Stem cell collection was
successful in 100 of 102 patients with a median CD34+ yield
of 5.5x103. A total of 98 patients (88%) continued treatment
with a single HDM (200 mg/m2) and ASCT. Four patients
were not eligible for HDM: one because of insufficient
CD34+ yield and three because of progression of disease
after stem cell collection. After treatment with HDM and
ASCT, 94 patients (85%) initiated consolidation therapy.
Four patients were not eligible for consolidation treatment
because of progression of disease (n=1), a delayed hemato-
logic recovery after ASCT (n=1), non-related disease (n=1),
and uncontrolled pain after ASCT (n=1). Nine patients dis-
continued consolidation treatment because of progressive
disease (n=2), thrombotic thrombocytopenic purpura (TTP)
(n=1), a TTP-like syndrome (n=1), overall worsening of
condition (n=1), grade 3 fatigue (n=1), refusal of further
treatment (n=2), and persisting PN (n=1). A total of 83
patients (75%) completed all four consolidation cycles. 
Efficacy
Table 2 shows response to induction, HDM/ASCT and
consolidation therapy. Response according to risk group
and R-ISS is shown in Table 3. Overall response after
induction therapy in all 111 patients was 93% with a CR
rate of 18%. The ≥ VGPR rate after induction therapy was
65% (95%CI: 55-74%) leading to rejection of the null
hypothesis, as the 95%CI is above 25%. The ≥ VGPR rate
increased to 77% after HDM/ASCT and to 86% after con-
solidation therapy. ORR increased to 94% after consolida-
tion therapy. CR rate after induction therapy between the
four different dose levels was comparable and increased
after consolidation therapy. At the three highest dose lev-
els, CR rate after consolidation therapy was higher in com-
parison to the lowest dose level (75%, 67% and 65% vs.
56%, respectively); however, this was not statistically sig-
nificant (test for trend, P=0.39; χ2 test, 27 mg/m2 vs. 36-56
mg/m2, P=0.16). Response after consolidation treatment
between standard risk patients and high-risk patients
(defined by ISS stage and cytogenetics) was similar with
CR rates of 67% versus 58%. Response after consolidation
therapy according to R-ISS stage (I, II and III) was compa-
rable with CR rates of 73%, 57% and 60%, respectively.
Median PFS in all 111 patients was 58 months (95%CI:
45-67 months). Dose level was not associated with PFS.
Median PFS in high-risk patients was worse compared to
standard risk patients (42 vs. 60 months; P=0.006), while
a higher R-ISS stage was also associated with a worse PFS
(P=0.04) (Figure 2). 
Median OS was 83 months and 5-year OS was 76%
(95%CI: 66-83%) (Figure 3). Dose level and risk status
were not associated with OS.
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Safety
Any grade hematologic toxicity occurred in 15% of
patients. Grade 3/4 hematologic toxicity occurred in 10%
of patients. At dose level 27 mg/m2, 36 mg/m2, 45 mg/m2
and 56 mg/m2, grade 3/4 hematologic toxicity occurred in
12%, 10%, 10% and 10%, respectively. Main grade 3/4
non-hematologic toxicity consisted of infections, respira-
tory disorders, skin and vascular disorders in 11%, 8%,
9%, and 9%, respectively. There was a gradual increase in
grade 3/4 infections from lower to higher doses of carfil-
R. Wester et al.
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Table 1. Baseline characteristics.
Characteristic                                 20/27 mg/m2              20/36 mg/m2               20/45 mg/m2                   20/56 mg/m2                 All patients 
Patients, n                                                           50                                         20                                          21                                               20                                        111
Male, n (%)                                                     34 (68)                               11 (55)                                 16 (76)                                       7 (35)                                 68 (61) 
Age, median (range), years                     58 (29-66)                          58 (47-64)                           56 (33-65)                                58 (37-65)                          58 (29-66)
ISS stage, n (%)                                                                                                                                                                                                                                        
1                                                                       18 (36)                                5 (25)                                  14 (67)                                       9 (45)                                 46 (41)
2                                                                       20 (40)                                7 (35)                                   4 (19)                                        7 (35)                                 38 (34)
3                                                                       12 (24)                                8 (40)                                   2 (10)                                        4 (20)                                 26 (23)
Unknown                                                         0 (0)                                    0 (0)                                     1 (5)                                          0 (0)                                    1 (1)
R-ISS stage, n (%)                                                                                                                                                                                                                                           
1                                                                        7 (14)                                 3 (15)                                  10 (48)                                       6 (30)                                 26 (23)
2                                                                       37 (74)                               10 (50)                                  7 (33)                                       11 (55)                                65 (59)
3                                                                         2 (4)                                   5 (25)                                    0 (0)                                         3 (15)                                  10 (9)
Unknown                                                         4 (8)                                   2 (10)                                   4 (19)                                         0 (0)                                   10 (9)
WHO performance status, n (%)                                                                                                                                                                                                          
0                                                                       24 (48)                                7 (35)                                  11 (52)                                      12 (60)                                54 (49)
1                                                                       20 (40)                               10 (50)                                  7 (33)                                        8 (40)                                 45 (41)
2                                                                         2 (4)                                    1 (5)                                     1 (5)                                          0 (0)                                    4 (4)
3                                                                         0 (0)                                    0 (0)                                    2 (10)                                         0 (0)                                    2 (2)
Unknown                                                         4 (8)                                   2 (10)                                    0 (0)                                          0 (0)                                    6 (5)
M-protein isotype, n (%)                                                                                                                                                                                                                        
IgA                                                                   11 (22)                                5 (25)                                   4 (19)                                        4 (20)                                 24 (22)
IgG                                                                  30 (60)                                8 (40)                                  10 (48)                                      11 (55)                                59 (53)
IgD                                                                    1 (2)                                    1 (5)                                     1 (5)                                          0 (0)                                    3 (3)
Light-chain disease                                     7 (14)                                 4 (20)                                   6 (29)                                        5 (25)                                 22 (20)
Unknown                                                         1 (2)                                   2 (10)                                    0 (0)                                          0 (0)                                    3 (3)
Genetic abnormalities, n (%)*                                                                                                                                                                                                                    
add 1q                                                                                                                                                                                                                                                               
Yes                                                                   5 (10)                                 4 (20)                                   2 (10)                                        7 (35)                                 18 (16)
No                                                                   35 (70)                               12 (60)                                 15 (71)                                      10 (50)                                72 (65)
Unknown                                                       10 (20)                                4 (20)                                   4 (19)                                        3 (15)                                 21 (19)
t(4;14)(p16;32)                                                                                                                                                                                                                                                
Yes                                                                    2 (4)                                   2 (10)                                    0 (0)                                         3 (15)                                   7 (6)
No                                                                   39 (78)                               14 (70)                                 19 (90)                                      13 (65)                                85 (77)
Unknown                                                        9 (18)                                 4 (20)                                   2 (10)                                        4 (20)                                 19 (17)
del(17p13)                                                                                                                                                                                                                                                         
Yes                                                                    3 (6)                                   2 (10)                                    1 (5)                                          1 (5)                                    7 (6)
No                                                                   38 (76)                               14 (70)                                 18 (86)                                      16 (80)                                86 (77)
Unknown                                                        9 (18)                                 4 (20)                                   2 (10)                                        3 (15)                                 18 (16)
t(11;14)(q13;q32)                                                                                                                                                                                                                                            
Yes                                                                   5 (10)                                   1 (5)                                    2 (10)                                         1 (5)                                    9 (8)
No                                                                   36 (72)                               15 (75)                                 17 (81)                                      15 (75)                                83 (75)
Unknown                                                        9 (18)                                 4 (20)                                   2 (10)                                        4 (20)                                 19 (17)
t(14;16)(q32;q23)                                                                                                                                                                                                                                            
Yes                                                                    3 (6)                                    1 (5)                                     0 (0)                                          0 (0)                                    4 (4)
No                                                                   38 (76)                               15 (75)                                 19 (90)                                      16 (80)                                88 (79)
Unknown                                                        9 (18)                                 4 (20)                                   2 (10)                                        4 (20)                                 19 (17)
Risk status, n (%)†                                                                                                                                                                                                                                    
High                                                                19 (38)                               10 (50)                                  4 (19)                                       10 (50)                                43 (39)
Standard                                                        21 (42)                                6 (30)                                  12 (57)                                       7 (35)                                 46 (41)
Unknown                                                       10 (20)                                4 (20)                                   5 (24)                                        3 (15)                                 22 (20)
Grade 1/2 PN, n (%)‡                                     3 (6)                                   2 (10)                                    0 (0)                                         2 (10)                                   7 (7)
PNP, polyneuropathy. *A total of 93 patients were evaluable. The table shows the presence of the genetic abnormality in all four dose levels together and in each dose level sep-
arately. †High-risk: t(4;14) and/or 17p- and/or add1q cytogenetic abnormalities and/or ISS stage 3 disease. Standard risk: the remaining patients with available cytogenetics and
ISS stage. ‡Not recorded in 9 patients. Ktd: carfilzomib, thalidomide and dexamethasone; n: number: HDM + ASCT: high-dose melphalan + autologous stem cell transplantation.
n: number; ISS: International Staging System; R-ISS: Revised International Staging System; WHO: World Health Organisation; PN: polyneuropathy. 
zomib (0%, 5%, 10%, and 15%, respectively) and consist-
ing mainly of  pneumonia (Online Supplementary Table S1). 
Table 4 summarizes cardiac AE. Any grade cardiac AE
were reported in 12% of patients after induction therapy
(14% in carfilzomib 27mg/m2, 15% in carfilzomib 36
mg/m2, 19% in carfilzomib 45 mg/m2, and 5% in carfil-
zomib 56 mg/m2). These cardiac events consisted mainly
of grade 1/2 toxicity (11 of 15 events). Five (5%) grade 3
cardiac AE were reported: three at dose level 27 mg/m2,
one at dose level 45 mg/m2, and one at dose level 56
mg/m2.
Any grade cardiac AE increased to 18% after consolida-
tion therapy with no reports of grade 4 AE at all four dose
levels, (18% in carfilzomib 27 mg/m2, 15% in carfilzomib
36 mg/m2, 19% in carfilzomib 45 mg/m2, and 15% in
carfilzomib 56 mg/m2). These cardiac events consisted
mainly of grade 1/2 toxicity (14  of 19 events). Five (5%)
grade 3 cardiac AE were reported.
Nine patients (8%) developed hypertension during
treatment (carfilzomib 27 mg/m2, n=3; carfilzomib 36
mg/m2, n=3; carfilzomib 45 mg/m2, n=2; carfilzomib 56
mg/m2, n=1); four (4%) of them had grade 3 toxicity. Five
(5%) patients needed antihypertensive treatment. 
Seven patients (6%) had pre-existing PN grade 1/2 and
two patients (2%) had pre-existing grade 3 PN. During
induction and consolidation therapy, 52 patients (47%)
developed PN. Grade ≥ 2 PN events occurred in 23
patients (20%) independently from carfilzomib dose;
these events were clinically manageable (carfilzomib 27
mg/m2, n=11; carfilzomib 36 mg/m2, n=3; carfilzomib 45
mg/m2, n=6; carfilzomib 56 mg/m2 n=3). Only one patient
(1%) reported grade 3 PN (carfilzomib 27 mg/m2). 
At least one serious AE (SAE) was reported in 43% of
patients. In cohort 1, an SAE was reported in 21 (42%)
patients, in cohort 2 in 8 (40%) patients, in cohort 3 in 7
(33%) patients, and in cohort 4 in 12 (60%) patients. 
As reported above, nine patients (8%) discontinued
treatment due to excessive toxicity: six patients during
induction therapy, and three patients during consolidation
therapy. In cohort 1, four (8%) patients went off protocol
due to AE: one (5%) patient in cohort 2 and four (20%)
patients in cohort 4. Table 5 shows an analysis of treat-
ment adherence to protocol. During consolidation treat-
ment, normal completion rate for carfilzomib and dexam-
ethasone was similar to induction treatment whereas this
was higher for thalidomide, probably due to the lower
dose of thalidomide during consolidation treatment. A
higher percentage of patients prematurely discontinued
treatment at the highest dose level of carfilzomib (5
patients, 30%). Four patients (20%) had excessive toxicity
Phase II CARTHADEX Study in NDMM
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Figure 1. Consort diagram. Cyclo: cyclophosphamide; G-CSF: granulocyte
colony-stimulating factor; HD: high dose; SC: stem cell. Ktd: carfilzomib, thalido-
mide and dexamethasone; n: number: HDM + ASCT: high-dose melphalan +
autologous stem cell transplantation.
Table 2. Response after induction, after high-dose melphalan (HDM) and after consolidation therapy. 
Dosing level carfilzomib                    20/27 mg/m2                   20/36 mg/m2               20/45 mg/m2               20/56 mg/m2                All patients
Patients, n                                                               50                                               20                                          21                                          20                                       111
Response after induction, n (%)                                                                                                                                                                                                              
sCR                                                                      4 (8)                                          1 (5)                                     0 (0)                                    1 (5)                                   6 (5)
≥ CR                                                                   8 (16)                                        5 (25)                                   3 (14)                                  4 (20)                                20 (18)
≥ VGPR                                                             27 (54)                                      16 (80)                                 13 (62)                                16 (80)                               72 (65)
≥ PR                                                                  45 (90)                                     20 (100)                                20 (95)                                18 (90)                              103 (93)
Response after HDM, n (%)                                                                                                                                                                                                                      
sCR                                                                     5 (10)                                        2 (10)                                   3 (14)                                   1 (5)                                 11 (10)
≥ CR                                                                  12 (24)                                       7 (35)                                   9 (43)                                  6 (30)                                34 (31)
≥ VGPR                                                             32 (64)                                      17 (85)                                 19 (90)                                18 (90)                               86 (77)
≥ PR                                                                  46 (92)                                     20 (100)                                20 (95)                                18 (90)                              104 (94)
Response after consolidation, n (%)                                                                                                                                                                                                      
sCR                                                                    17 (34)                                       4 (20)                                   8 (38)                                  4 (20)                                33 (30)
≥ CR                                                                  28 (56)                                      15 (75)                                 14 (67)                                13 (65)                               70 (63)
≥ VGPR                                                             40 (80)                                      18 (90)                                 20 (95)                                18 (90)                               96 (86)
≥ PR                                                                    46 (92)                                     20 (100)                                20 (95)                                18 (90)                              104 (94)
n: number; sCR: stringent complete remission; CR: complete remission; VGPR: very good partial response; PR: partial response.
excessive toxicity
not eligible for consolidation
excessive toxicity
and two patients (10%) asked to discontinue treatment
(Online Supplementary Table S2). 
Discussion
Results of the first three dose levels of this phase II trial
have been published before.11 In this paper, we discuss the
results of four dose levels of carfilzomib. As reported
above, treatment with KTd for induction and consolida-
tion in transplant eligible patients with NDMM is safe,
tolerable and effective. We included the additional cohort
with the highest dose level of 56 mg/m2, based on the
hypothesis that a higher dose level induces a higher
response rate.12,16 Response after induction was high, with
65% of patients reaching at least VGPR, increasing to 86%
after consolidation therapy. CR rate after consolidation
was high at 63%. Response (i.e. >CR) after consolidation
at the three higher dose levels (20/36, 20/45, 20/56) was
better than at the lowest dose level (20/27); however, the
small sample size and the non-randomized design of the
study preclude firm conclusions about superiority of the
highest dose levels. In the ARROW trial, 478 patients with
RRMM were randomized between treatment with carfil-
zomib twice a week 27 mg/m2 or once weekly 70 mg/m2.
PFS was higher with once weekly 70 mg/m2 than with
twice weekly 27 mg/m2 (11.2 months vs. 7.6 months).20
These data and our data (based on response) suggest that
a dose of at least 36 mg/m2 twice weekly (which equals 70
mg/m2 once weekly) would be the preferred dose.
An important remaining question relates to the efficacy
of this regimen in high-risk patients. In this trial with lim-
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2270 haematologica | 2019; 104(11)
Table 3. Response after consolidation therapy according to risk status and R-ISS.
                                             Standard risk*                 High-risk*                  R-ISS 1                      R-ISS 2                        R-ISS 3                     Total
Patients, n                                               46                                         43                                   26                                     65                                       10                                111
sCR, n (%)                                        16 (35)                                 9 (21)                           10 (38)                           19 (29)                               0 (0)                          33 (30)
≥ CR, n (%)                                      31 (67)                                25 (58)                          19 (73)                           37 (57)                              6 (60)                        70 (63)
≥ VGPR, n (%)                                 40 (87)                                36 (84)                          24 (92)                           54 (83)                              9 (90)                        96 (86)
≥ PR, n (%)                                      44 (96)                                38 (88)                         26 (100)                          58 (91)                            10 (100)                     104 (94)
*High-risk: t(4;14) and/or 17p- and/or add1q cytogenetic abnormalities and/or ISS stage 3 disease. Standard risk: the remaining patients with available cytogenetics and ISS stage.
n: number; ISS: International Staging System; R-ISS: Revised International Staging System; sCR: stringent complete remission; CR: complete remission; VGPR: very good partial
response; PR: partial response.
Figure 2. Kaplan-Meier curves of progression-free survival (PFS). (A) PFS in all 111 patients. (B) PFS per dose level. (C) PFS according to risk status. (D) PFS according
to Revised-International Staging System.                
A
C
B
D
Logrank P=0.94
Logrank P=0.04Logrank P=0.006
ited numbers, the negative impact of high-risk cytogenet-
ics was not abrogated by carfilzomib.21 At the same time,
overall risk status, based on cytogenetics and ISS stage,
was not significantly associated with response. However,
high-risk patients and patients with a higher R-ISS score
had a significantly worse PFS. Median PFS and OS for all
patients were 58 months and 83 months, respectively.
These data show that treatment with KTd is effective as
front-line treatment of transplant eligible patients with
NDMM. Also, this regimen had no effect on stem cell
mobilization and collection, with the exception of two
patients in whom stem cell collection failed. Several phase
II trials have investigated treatment with carfilzomib in
NDMM using different regimens.12-15 For example, in the
CYKLONE trial, cyclophosphamide was added to the KTd
regimen; this showed a comparable ORR of 91% and a
PFS at 24 months of 76%. In this study, MTD was 20/36
mg/m2.13 In comparison, in the Carthadex trial, dose levels
of 45 mg/m2 and 56 mg/m2 were well tolerated without
additional toxicity compared to dose levels 27 mg/m2 and
36 mg/m2. The number of patients going off treatment due
to excessive toxicity was low: 9 out of 111 patients (8%).
Our data show that efficacy and safety are comparable at
dose levels 36 mg/m2 and upward. Main grade 3/4 non-
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Table 4. Cardiac adverse events between dose levels.
                                                  20/27 mg/m2, n=50               20/36 mg/m2, n=20             20/45 mg/m2, n=21                20/56 mg/m2, n=20
Cardiac toxicity, n (%)              Grade 1/2         Grade 3/4        Grade 1/2      Grade 3/4         Grade 1/2     Grade 3/4         Grade 1/2       Grade 3/4
Acute coronary syndrome               0 (0)                      0 (0)                   1 (5)                 0 (0)                    0 (0)                 0 (0)                       0 (0)                   0 (0)
Atrial flutter                                        1 (2)                      0 (0)                   0 (0)                 0 (0)                    0 (0)                 0 (0)                       0 (0)                   0 (0)
Atrial fibrillation                                 1 (2)                      0 (0)                   0 (0)                 0 (0)                    0 (0)                 0 (0)                       0 (0)                   0 (0)
Angina pectoris                                  3 (6)                      0 (0)                   1 (5)                 0 (0)                   2 (10)                1 (5)                       1 (5)                   0 (0)
Congestive heart failure                  1 (2)                      2 (4)                   1 (5)                 0 (0)                    0 (0)                 0 (0)                       0 (0)                   1 (5)
Dyspnea                                               0 (0)                      1 (2)                   0 (0)                 0 (0)                    0 (0)                 0 (0)                       0 (0)                   0 (0)
Palpitations                                         1 (2)                      0 (0)                   1 (5)                 0 (0)                    1 (5)                 0 (0)                       0 (0)                   0 (0)
Pericardial fluid                                  0 (0)                      0 (0)                   0 (0)                 0 (0)                    0 (0)                 0 (0)                       1 (5)                   0 (0)
Total of cardiac events                    7 (14)                     3 (6)                  4 (20)                0 (0)                   3 (14)                 (5)                        1 (5)                   1 (5)
n: number.
Figure 3. Kaplan-Meier curves overall survival (OS). (A) OS in all 111 patients. (B) OS per dose level. (C) OS according to risk status. (D) OS according to Revised-
International Staging System.                  
A B
C D
Logrank P=0.23 Logrank P=0.56
Logrank P=0.70
hematologic toxicity consisted of infections, respiratory,
skin, and vascular disorders. The rate of cardiac AE was
low in this trial. Five patients (5%) experienced grade 3
cardiac AE, including congestive heart failure, dyspnea
and chest pain. This is comparable to other trials investi-
gating carfilzomib in NDMM.12-14 The rate of grade 3/4 car-
diac toxicity is slightly higher in RRMM, most likely
because patients are older and due to previous treat-
ment.9,10 However, the limited number of patients pre-
clude firm conclusions about safety regarding cardiac
events between the different dose levels. Jakubowiak et al.
performed a phase I/II trial of carfilzomib combined with
lenalidomide and dexamethasone (CRd). In this trial,
patients not proceeding to ASCT continued treatment
with CRd beyond eight cycles with a median of 12 cycles.
PFS at 24 months was 92%.12 However, thalidomide
remains a valuable treatment option in many countries,
due to its availability and low costs, and offers an excel-
lent alternative to treatment with lenalidomide.
Recently, several trials have been performed in patients
with NDMM,  using alternative schedules for induction
and consolidation. The Intergroupe Francophone du
Myélome (IFM) performed a phase II trial of lenalidomide
combined with bortezomib and dexamethasone (RVD)
for induction and consolidation. PFS at three years was
77% and CR  was 58%. Most common toxicities were
grade 1/2 PN in 55%.22 In the EMN02 trial, VCD for induc-
tion was followed by VRD for consolidation treatment.
CR rate was 55% and PFS not reached at 60 months.23
Although it should be taken into account that this is a
cross comparison between trials, the Carthadex trial effi-
cacy data are similar with median PFS of 58 months and
CR rate of 63%, and acceptable toxicity. Moreover, the
combination of carfilzomib, thalidomide and dexametha-
sone is an affordable treatment regimen. These data sug-
gest that KTd is an effective and safe induction and con-
solidation regimen in newly diagnosed MM. 
In conclusion, the combination of carfilzomib, thalido-
mide and low-dose dexamethasone appears highly effica-
cious and safe in transplant-eligible patients with NDMM
across all dose levels with manageable toxicities.
Consolidation therapy after ASCT results in a major
improvement in response. In addition, we observed that
higher dose levels of carfilzomib (36-56 mg/m2)  result in
better response rates after consolidation therapy. Current
studies in newly diagnosed MM patients are performed
using 36 mg/m2 twice weekly. The preferred dose to be
used in practice would be 36 mg/m2 twice weekly (or 70
mg/m2 once weekly), which we would recommend based
on our carthadex response data.  Results of cohort 5, in
which patients were treated with eight instead of four
induction cycles, will follow in the near future. 
Further randomized, prospective studies are needed to
confirm these data and determine the place for carfil-
zomib in the treatment of patients with NDMM.
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Table 5. Adherence to treatment protocol during induction and consol-
idation.
Kolom1                                             Induction             Consolidation
                                                           (N=111)                    (N=94)
Carfilzomib                                                          
Normal completion                                  68 (61)                          61 (55)
Dose delay, reduction and/or                37 (33)                          24 (22)
interruption
Premature stop                                           6 (5)                             9 (10)
Thalidomide                                                                                               
Normal completion                                  54 (49)                          63 (67)
Dose delay, reduction and/or                42 (38)                            8 (9)
interruption
Premature stop                                        15 (14)a                         23 (24)b
Dexamethasone                                                                                        
Normal completion                                  85 (77)                          66 (70)
Dose delay, reduction and/or                20 (18)                          18 (19)
interruption
Premature stop                                           6 (5)                           10 (11)
aIncluding 9 patients who received no thalidomide during induction cycle 4.
bIncluding 14 patients who received no thalidomide during consolidation cycle 4. n:
number.
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